Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC and UCHL1.

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N.

http://www.ncbi.nlm.nih.gov/pubmed/24309322